Focusing On The Bigger Picture At The EMA
Top Agency Exec Talks Life Beyond Brexit And Coronavirus
Tony Humphreys of the European Medicines Agency explains the thinking behind the agency’s regulatory science strategy, why the PRIME scheme is to get a boost, and why the need to tackle health threats ranked so low in a stakeholder consultation.
You may also be interested in...
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
A parliamentary committee has come up with some ideas for strengthening the UK’s response to future demand surges due to the spread of COVID-19.
The European Medicines Agency is preparing to appoint its new executive director after nominee Emer Cooke presented her case to the European Parliament.